Background: Atopic dermatitis (AD) is an inflammatory skin disease affecting 10% to 20% of children and 1% to 3% of adults in industrialized countries. Enhanced expression of IL-31 is detected in skin samples of patients with AD, but its physiological relevance is not known. Objective: We sought to determine the role of IL-31 in skin differentiation. Methods: We used human 3-dimensional organotypic skin models with either primary keratinocytes or HaCaT keratinocytes with inducible IL-31 receptor alpha to evaluate the effect of IL-31. The consequences were studied by using histology, the expression of markers analyzed by immunofluoresence and quantitative RT-PCR, and gene expression arrays. Results: We observed that IL-31 interferes with keratinocyte differentiation. Gene expression analysis revealed a limited set of genes deregulated in response to IL-31, including IL20 and IL24. In HaCaT keratinocytes with inducible IL-31 receptor alpha, IL-31 inhibited proliferation upon induction of IL-31 receptor alpha by inducing cell cycle arrest. As in primary cells, IL-31-treated HaCaT cells elicited a differentiation defect in organotypic skin models, associated with reduced epidermal thickness, disturbed epidermal constitution, altered alignment of the stratum basale, and poor development of the stratum granulosum. The differentiation defect was associated with a profound repression of terminal differentiation markers, including filaggrin, an essential factor for skin barrier formation, and a reduced lipid envelope. The highly induced proinflammatory cytokines IL-20 and IL-24 were responsible for part of the effect on FLG expression and thus for terminal differentiation. Conclusion: Our study suggests that IL-31 is an important regulator of keratinocyte differentiation and demonstrates a link between the presence of IL-31 in skin, as found in patients with AD, and filaggrin expression. (J Allergy Clin Immunol 2012;129:426-33.)
机构:
Chugai Pharmaceut Co Ltd, Div Res, Gotemba, Shizuoka 4128513, JapanChugai Pharmaceut Co Ltd, Div Res, Gotemba, Shizuoka 4128513, Japan
Kato, Atsuhiko
Fujii, Etsuko
论文数: 0引用数: 0
h-index: 0
机构:
Chugai Pharmaceut Co Ltd, Div Res, Gotemba, Shizuoka 4128513, JapanChugai Pharmaceut Co Ltd, Div Res, Gotemba, Shizuoka 4128513, Japan
Fujii, Etsuko
Watanabe, Takeshi
论文数: 0引用数: 0
h-index: 0
机构:
Chugai Res Inst Med Sci Inc, Gotemba, Shizuoka 4128513, JapanChugai Pharmaceut Co Ltd, Div Res, Gotemba, Shizuoka 4128513, Japan
Watanabe, Takeshi
Takashima, Yoshiaki
论文数: 0引用数: 0
h-index: 0
机构:
Chugai Pharmaceut Co Ltd, Div Res, Gotemba, Shizuoka 4128513, JapanChugai Pharmaceut Co Ltd, Div Res, Gotemba, Shizuoka 4128513, Japan
Takashima, Yoshiaki
Matsushita, Hiroaki
论文数: 0引用数: 0
h-index: 0
机构:
Chugai Pharmaceut Co Ltd, Div Res, Gotemba, Shizuoka 4128513, JapanChugai Pharmaceut Co Ltd, Div Res, Gotemba, Shizuoka 4128513, Japan
Matsushita, Hiroaki
Furuhashi, Takuya
论文数: 0引用数: 0
h-index: 0
机构:
Nagoya City Univ, Grad Sch Med Sci, Dept Geriatr & Environm Dermatol, Mizuho Ku, Nagoya, Aichi 4678602, JapanChugai Pharmaceut Co Ltd, Div Res, Gotemba, Shizuoka 4128513, Japan
Furuhashi, Takuya
Morita, Akimichi
论文数: 0引用数: 0
h-index: 0
机构:
Nagoya City Univ, Grad Sch Med Sci, Dept Geriatr & Environm Dermatol, Mizuho Ku, Nagoya, Aichi 4678602, JapanChugai Pharmaceut Co Ltd, Div Res, Gotemba, Shizuoka 4128513, Japan